Genmab vs Illumina
Genmab (GMAB), health care, and Illumina (ILMN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Genmab is worth $32B on the stock market and Illumina $30.6B: Genmab is valued at 5% more. Genmab trades at 44.4 times earnings and Illumina at 34.9; operating margins in their latest fiscal years were 28.6% and 18.6%. Over the past year Genmab's share price has moved +70.1% and Illumina's +62.3%.
Key facts
- Genmab market value
- $32B
- Illumina market value
- $30.6B
- Genmab P/E
- 44.4
- Illumina P/E
- 34.9
- Genmab revenue
- $3.7BFY to 2025-12-31
- Illumina revenue
- $4.3BFY to 2025-12-28
- Superinvestors holding both
- 0
Market values as of .
| Measure | Genmab | Illumina |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-28 |
| Size | ||
| Market cap | $32Bhigher | $30.6Blower |
| Revenue | $3.7Blower | $4.3Bhigher |
| Earnings | $963Mhigher | $850Mlower |
| Employees | 3,244lower | 8,600higher |
| Total assets | $12.9Bhigher | $6.6Blower |
| Valuation | ||
| P/E | 44.4higher | 34.9lower |
| P/S | 8.6higher | 7.1lower |
| P/B | — | 9.8 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 28.6%higher | 18.6%lower |
| Balance sheet | ||
| Net assets | $5.8Bhigher | $2.7Blower |
| Total liabilities | $7Bhigher | $3.9Blower |
| Total debt | $5.3B | — |
| Cash on hand | $1.7Bhigher | $1.4Blower |
| Price change | ||
| Today | +0.76%lower | +2.33%higher |
| 1 year | +70.1%higher | +62.3%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Genmab only (1)
- Louis Bacon0.3%
Illumina only (11)
- Keith Meister15.5%
- Richard Mashaal6.3%
- Zach Schreiber2.7%
- Cathie Wood1.3%
- Primecap team0.6%
- Diamond Hill team0.4%
- Baillie Gifford team0.3%
- Jim Simons (1938–2024)0.2%
- Cliff Asness0.2%
- Joel Greenblatt0.1%
- Ron Baron0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns GMAB · Who owns ILMN
More on Genmab
Further comparisons
Genmab against its closest peers
Illumina against its closest peers
Learn
Questions and answers
Which is bigger, Genmab or Illumina?
By market value, Genmab is the larger: $32B against $30.6B for Illumina. By revenue in its latest fiscal year, Illumina is the larger: $4.3B against $3.7B for Genmab.
Which has the higher P/E ratio?
Genmab: 44.4, against 34.9 for Illumina. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Genmab: 28.6%, against 18.6% for Illumina. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Genmab and Illumina?
None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Genmab and 11 hold Illumina.
Cite this page
Funkfolio, “Genmab vs Illumina”, data as of 18 November 2026. https://funkfolio.com/compare/gmab-vs-ilmn
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.